EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens

Michael R Schlabach, Sharon Lin, Zachary R Collester, Christopher Wrocklage, Sol Shenker, Conor Calnan, Tianlei Xu, Hugh S Gannon, Leila J Williams, Frank Thompson, Paul R Dunbar, Robert A LaMothe und 16 weitere

Journal of Clinical Investigation · 15.12.2023 · 133 (24)

DOI: 10.1172/jci163096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.12.2023. Verfasst von Michael R Schlabach und 27 weiteren Autor:innen. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KSQ Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsNeoplasmsHumansAnimalsMiceRNA, Guide, CRISPR-Cas SystemsLymphocytes, Tumor-InfiltratingImmunotherapy, AdoptiveGene EditingSuppressor of Cytokine Signaling 1 Protein

Stichwörter der Autor:innen

Cancer immunotherapyGene therapyImmunologyT cellsTherapeutics

Substanzen

RNA, Guide, CRISPR-Cas SystemsSOCS1 protein, humanSuppressor of Cytokine Signaling 1 Protein

Förderung

  • KSQ Therapeutics

Zitieren

APA

Schlabach, M. R., Lin, S., Collester, Z. R., Wrocklage, C., Shenker, S., Calnan, C., Xu, T., Gannon, H. S., Williams, L. J., Thompson, F., Dunbar, P. R., LaMothe, R. A., Garrett, T. E., Colletti, N., Hohmann, A. F., Tubo, N. J., Bullock, C. P., Le Mercier, I., Sofjan, K., …, & Benson, M. J. (2023). Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens. Journal of Clinical Investigation, 133(24). https://doi.org/10.1172/jci163096

Vancouver

Schlabach MR, Lin S, Collester ZR, Wrocklage C, Shenker S, Calnan C, et al. Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens. Journal of Clinical Investigation. 2023;133(24). doi:10.1172/jci163096

BibTeX
@article{Schlabach2023,
  author = {Schlabach, Michael R and Lin, Sharon and Collester, Zachary R and Wrocklage, Christopher and Shenker, Sol and Calnan, Conor and Xu, Tianlei and Gannon, Hugh S and Williams, Leila J and Thompson, Frank and Dunbar, Paul R and LaMothe, Robert A and Garrett, Tracy E and Colletti, Nicholas and Hohmann, Anja F and Tubo, Noah J and Bullock, Caroline P and Le Mercier, Isabelle and Sofjan, Katri and Merkin, Jason J and Keegan, Sean and Kryukov, Gregory V and Dugopolski, Caroline and Stegmeier, Frank and Wong, Karrie and Sharp, Fiona A and Cadzow, Louise and Benson, Micah J},
  title = {Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {24},
  doi = {10.1172/jci163096}
}
Kostenlos starten →